Skip to Content

Plerixafor Dosage

Medically reviewed on December 15, 2017.

Applies to the following strengths: 20 mg/mL

Usual Adult Dose for non-Hodgkin's Lymphoma

Dosing Based on Actual Patient Body Weight:
-83 kg or Less:
20 mg fixed dose or 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

-Greater than 83 kg and Less than 160 kg:
0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

Duration of Therapy: Up to 4 consecutive days

Maximum Dose: 40 mg/day

Comments:
-The drug volume to be administered should be calculated using the following equation: 0.012 x actual patient body weight (kg) = administration dose (mL)
-The dosing has been calculated based on actual patient body weight up to 175% of ideal body weight; dosing and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
-Granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg should be administered once daily in the morning for 4 consecutive days prior to the first dose of this drug and on each morning prior to apheresis.

Use: Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Usual Adult Dose for Multiple Myeloma

Dosing Based on Actual Patient Body Weight:
-83 kg or Less:
20 mg fixed dose or 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

-Greater than 83 kg and Less than 160 kg:
0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

Duration of Therapy: Up to 4 consecutive days

Maximum Dose: 40 mg/day

Comments:
-The drug volume to be administered should be calculated using the following equation: 0.012 x actual patient body weight (kg) = administration dose (mL)
-The dosing has been calculated based on actual patient body weight up to 175% of ideal body weight; dosing and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
-Granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg should be administered once daily in the morning for 4 consecutive days prior to the first dose of this drug and on each morning prior to apheresis.

Use: Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Renal Dose Adjustments

Moderate and Severe Renal Impairment (CrCl 50 mL/min or less):
Dosing Based on Actual Patient Body Weight:
-83 kg or Less:
13 mg or 0.16 mg/kg subcutaneously once a day

-Greater than 83 kg and Less than 160 kg:
0.16 mg/kg subcutaneously once a day

Duration of Therapy: Up to 4 consecutive days

Maximum Dose: 27 mg/day

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

-Hemodialysis: Insufficient data available to make dosage recommendation.
-Peritoneal dialysis: Data not available

Other Comments

Administration Advice:
-Subcutaneous injection to the abdomen was primarily used in clinical trials, but some patients received subcutaneous injections in the extremities.
-Prior to administration, each drug vial should be inspected visually and should not be used if there is particulate matter or if the solution is discolored.

Storage Requirements:
-Each drug vial is for single use only; any unused drug should be discarded.

Monitoring:
-Hematologic: White blood cell counts, platelet counts (during treatment and apheresis)
-Hypersensitivity/Immunologic: Signs/symptoms of hypersensitivity (during and after drug administration)

Patient Advice:
-This drug may cause side effects such as dizziness and fatigue that can affect your ability to perform certain activities; avoid driving and activities such as operating machinery until you know how this drug affects you.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide